A Non-Viral Gene Therapy Approach to IL-12 Delivery for The Treatment of Cancer

Time: 8:30 am
day: Day Two


  • Understand how local delivery of IL-12 without significant systemic toxicity is feasible with a non-viral gene therapy approach that involves administration of an IL-12 plasmid with a synthetic DNA delivery system (GEN-1)
  • Learn how weekly administration of GEN-1 into peritoneal cavity yields durable increases in IL-12 and IFN-g and the treatment is tolerable upon repeat administration over several weeks
  • Explore why repeated weekly administration of GEN-1 in combination with standard chemotherapy remodels the tumour immune environment favouring immune stimulation over immune suppression